Eyesiu Medicines

Executive Summary

Eyesiu Medicines is a Dutch pre-clinical company specializing in fast-acting sprays and shampoos containing palmitoylethanolamide (PEA) and nicotinamide (vitamin B3). Founded in 2019 and based in Leiden, the company focuses on orthomolecular therapy for chronic pain, inflammation, and neurovascular conditions, with products also marketed for hair loss. Despite its early stage and lack of disclosed pipeline or funding, Eyesiu appears to have commercialized nutraceutical products in the Netherlands. The company's strategy leverages natural ingredients targeting the brain, eyes, lungs, skin, and hair, appealing to the growing demand for non-pharmaceutical alternatives. However, the absence of clinical trial data or regulatory milestones limits its credibility as a biotech investment. The competitive landscape includes numerous supplement companies, and Eyesiu's differentiation through spray formulation and PEA mechanism offers some potential. Overall, Eyesiu is a micro-cap with high uncertainty and low prospective returns without clear catalysts.

Upcoming Catalysts (preview)

• Q3 2026Licensing agreement for EU distribution of PEA spray25% success
• Q1 2027Initiation of a clinical trial for PEA in neuropathic pain15% success
• Q4 2026Launch of a new brain health supplement under existing brand40% success